GlaxoSmithKline PLC is setting up a new company with Verily Life Sciences LLC (formerly Google Life Sciences) called Galvani Bioelectronics. Galvani, which will be 55% owned by GSK and 45% by Verily, will work to develop and commercialize bioelectronic medicines.
Moncef Slaoui (currently GSK's vaccines chief but the former head of R&D), will chair the board of the new company....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?